Physician profile
Jamie Casey
NPI 1770020901
$1,220.64
in general payments reported to CMS, 2019-2025
20 companies · $777 in 2025
The $777 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.87 · 2023: $31.30 · 2024: $384 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.17 | 2024-2025 | |
| Glaxosmithkline, LLC. | $223.71 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $166.74 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $136.17 | 2024-2025 | Lokelma, Airsupra |
| Novo Nordisk INC | $79.73 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Eisai INC. | $56.27 | 2024 | |
| Exact Sciences Corporation | $44.73 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Verona Pharma, INC. | $41.57 | 2025 | Ohtuvayre |
| Lundbeck LLC | $27.77 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.39 | 2025 | Caplyta |
| Viatris Specialty LLC | $24.07 | 2025 | Yupelri |
| Boston Scientific Corporation | $22.05 | 2025 | Watchman Access System |
| Lilly USA, LLC | $18.85 | 2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.43 | 2025 | Jardiance |
| Dexcom, INC. | $18.29 | 2024 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $18.11 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $17.27 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $14.32 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.57 | 2024 | Zoryve |
| Amgen INC. | $13.43 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.